The Firm continues its momentum as a partner of choice in the pharmaceutical service space
Chicago, IL, October 8, 2022 — The Vistria Group today announced a strategic investment in the pharmaceutical Contract Development and Manufacturing Organization (CDMO), Alcami (“the Company”). Holding equal controlling interest with European specialist investor, GHO Capital Partners LLP, the deal marks The Vistria Group’s tenth transaction from Vistria Fund IV, LP and sixth investment in pharmaceutical services across The Vistria Group’s prior Funds.
“For more than 40 years, Alcami has delivered a strong suite of services to pharmaceutical companies,” says Natasha Latif, Principal at The Vistria Group. “This deal not only signifies our continued momentum in the pharmaceutical services space but also showcases our value as a recognized partner of choice. We’re thrilled to work alongside Alcami’s leadership team to enhance their strategic offering.”
Headquartered in North Carolina, Alcami has built a strong offering, market position and reputation in high-growth specialties, including drug product manufacturing focusing on sterile fill-finish of both biologics and small molecules; formulation development; lab services; and cGMP biostorage of high-value temperature-sensitive biologics, pharmaceuticals and materials.
“Alcami is the ideal platform in the CDMO and lab services areas that we have been targeting for quite some time,” says Jon Maschmeyer, Senior Partner and Co-Head of Healthcare at The Vistria Group. “This partnership reinforces The Vistria Group’s thematic approach in the pharmaceutical space, and we’re excited to partner with them in their next chapter of growth.”
Alcami enacted a major strategic transformation, further enhancing the growth profile of the business. Building on a strong service offering, Alcami acquired a world-class sterile fill-finish operation in TriPharm Services, and in December 2021 acquired Masy BioServices, a premier cGMP biostorage and pharma services business. In addition, Alcami has invested over $140 million in capital expenditure to add five state-of-the-art sterile fill-finish manufacturing lines and additional laboratory space to support both biologic and small molecule programs.
“This is an ideal partnership in furthering Alcami’s strategic transformation, unprecedented growth rate and comprehensive service offerings valued by over 1,000 clients around the globe,” says Alcami Chairman and CEO Patrick Walsh. “The Vistria Group and GHO have excellent reputations for partnering with high growth companies that create value for all stakeholders and we look forward to further scaling our offering, capacity and geographic reach with our new partners.”
The Vistria Group and GHO Capital will acquire a 50/50 controlling interest in Alcami from Madison Dearborn Partners and Ampersand Capital. Ampersand Capital and Alcami Management will reinvest significant equity as part of the acquisition.
About Alcami
Alcami is a contract development and manufacturing organization headquartered in North Carolina with over 40 years of experience advancing products through every development lifecycle stage. Leveraging 675,000 ft² across the United States, Alcami serves pharmaceutical and biotech companies of all sizes providing customizable and innovative solutions for analytical development, clinical to commercial sterile and oral solid manufacturing, packaging, microbiology, cGMP biostorage, environmental monitoring, and pharmaceutical support services. Alcami’s private equity ownership includes GHO Capital, The Vistria Group, and Ampersand Capital Partners. For more information, please visit alcaminow.com.
About The Vistria Group
The Vistria Group is building a new kind of private investment firm that seeks to deliver both financial returns and societal impact. It invests in essential industries like healthcare, knowledge and learning, and financial services that deliver value for investors as well as communities, employees, and consumers. The Vistria Group works as a true partner with its portfolio companies, drawing on its deep sector knowledge, operational expertise, unique network, diverse team, and impact orientation to achieve transformational growth. With over $8 billion in AUM, The Vistria Group believes it has delivered attractive returns for its investors while achieving positive outcomes for its portfolio companies, and the lives and livelihoods it supports.
